EX-1 2 exhibit_1.htm EXHIBIT 1
Exhibit 1

 

For Immediate Release

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
 
- Reports continued progress in the evaluation of assets for potential pipeline expansion in the
areas of oncology and rare disease; transaction targeted for 2025 -
 
- Provides updated and extended cash runway guidance into H1 2027 -
 
- Management to host conference call today, August 14th, at 8:30 am EDT -

TEL AVIV, Israel, August 14, 2025 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2025, and provided a corporate update.
 
“Since our last quarterly update, we have been acutely focused on evaluating a broad range of potential pipeline expansion opportunities where we can leverage our clinical and regulatory expertise, and track record of drug approval success, to drive new innovation in areas of need,” said Philip Serlin, Chief Executive Officer of BioLineRx. “Today, I am pleased to report that discussions with potential partners continue to progress. Our balance sheet is strong, our organization is lean, and we are seeing promising opportunities that fit well within our criteria - most notably a clear and efficient development pathway. I remain confident that we could potentially execute a transaction this year that will expand our pipeline and provide fresh opportunities for clinical success and long-term value creation.”
 
Financial Updates


 •
With $28.2 million on its balance sheet as of June 30, 2025, BioLineRx is guiding to a cash runway into the first half of 2027. This represents an improvement as compared to the Company’s previous cash runway guidance into the second half of 2026.
 
Clinical Updates

Motixafortide

Pancreatic Ductal Adenocarcinoma (mPDAC)


 •
Enrollment activities continue in the CheMo4METPANC Phase 2b clinical trial, which is being led by Columbia University, and supported by both Regeneron and BioLineRx. The CheMo4METPANC trial is evaluating motixafortide in combination with the PD-1 inhibitor cemiplimab and standard chemotherapy (gemcitabine and nab-paclitaxel).
 

 •
A prespecified interim analysis is planned when 40% of progression-free survival (PFS) events are observed.
 

 •
An abstract featuring updated data from the pilot phase of the ongoing CheMo4METPANC clinical trial was presented at the 2025 ASCO Annual Meeting in May. Key highlights include:
 

 o
Four of 11 patients remained progression-free after more than one year.
 

 o
Two patients underwent definitive treatment for metastatic pancreatic cancer: one had complete resolution of all radiologically detected liver lesions and underwent radiation to the primary pancreatic tumor, and one had a sustained partial response and underwent pancreaticoduodenectomy with pathology demonstrating a complete response.
 

 o
An analysis of pre- and on-treatment biopsies revealed that CD8+ T-cell tumor infiltration increased across all eleven patients treated with the motixafortide combination.
 
Sickle Cell Disease (SCD) & Gene Therapy


 •
Ongoing Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for stem cell mobilization for gene therapies in sickle cell disease continues to progress. The trial is sponsored by Washington University School of Medicine in St. Louis, and results are anticipated in the second half of 2025.
 

 •
A second study, sponsored by St. Jude Children's Research Hospital, continues to enroll patients. The study is a multi-center Phase 1 clinical trial evaluating motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with Sickle Cell Disease (SCD).
 
APHEXDA Performance Update


 •
APHEXDA generated sales of $1.7 million in the second quarter of 2025, providing royalty revenue to the Company of $0.3 million.
 
Financial Results for the Quarter Ended June 30, 2025
 

 •
Total revenues for the second quarter of 2025 were $0.3 million, reflecting the royalties paid by Ayrmid from the commercialization of APHEXDA in stem cell mobilization in the U.S. Total revenues in 2025 are not comparable to the same period in 2024, which included direct commercial sales by BioLineRx prior to the Ayrmid transaction in November 2024.
 

 •
Cost of revenues for the second quarter of 2025 was immaterial, compared to cost of revenues of $0.9 million for the second quarter of 2024. Cost of revenues in 2025 are not comparable to the same period in 2024, which included cost of sales from direct commercial sales by BioLineRx prior to the Ayrmid transaction in November 2024.
 

 •
Research and development expenses for the second quarter of 2025 were $2.3 million, compared to $2.2 million for the second quarter of 2024. The increase resulted primarily from certain one-time costs associated with the PDAC study at Columbia University, offset by lower expenses related to motixafortide due to the out-licensing of U.S. rights to Ayrmid, as well as a decrease in payroll and share-based compensation, primarily due to a decrease in headcount.
 
2

 •
There were no sales and marketing expenses for the second quarter of 2025, compared to $6.4 million for the second quarter of 2024. The decrease resulted primarily from the shutdown of U.S. commercial operations in the fourth quarter of 2024 following the Ayrmid transaction.
 

 •
General and administrative expenses for the second quarter of 2025 were $0.2 million, compared to $1.6 million for the second quarter of 2024. The decrease resulted primarily from the reversal of a provision for doubtful accounts following receipt of an overdue milestone payment from Gloria, a decrease in payroll and share-based compensation, primarily due to a decrease in headcount, as well as small decreases in a number of general and administrative expenses.
 

 •
Net non-operating expenses for the second quarter of 2025 were $1.9 million, compared to net non-operating income of $7.8 million for the second quarter of 2024. Non-operating income (expenses) for both periods primarily relate to fair-value adjustments of warrant liabilities on the balance sheet, as a result of changes in the Company’s share price
 

 •
Net financial income for the second quarter of 2025 was $0.2 million, compared to net financial expenses of $1.6 million for the second quarter of 2024. Net financial income (expenses) for both periods primarily relate to loan interest paid, partially offset by investment income earned on bank deposits and gains on foreign currency (primarily NIS) cash balances due to the strengthening of the NIS during the period. The significant decrease in financial expenses in the 2025 period results from a substantial paydown of the BlackRock loan balance in November 2024, following the transaction with Ayrmid.
 

 •
Net loss for the second quarter of 2025 was $3.9 million, compared to net income of $0.5 million for the second quarter of 2024.
 

 •
As of June 30, 2025, the Company had cash, cash equivalents, and short-term bank deposits of $28.2 million, sufficient to fund operations, as currently planned, into the first half of 2027.
 
Conference Call and Webcast Information

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until August 16, 2025; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.
 
About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.
 
In addition, BioLineRx is in discussions to expand its pipeline in the areas of oncology and/or rare diseases, where the Company can utilize its end-to-end expertise in drug development, regulatory affairs and manufacturing to bring life-changing innovation from bench to bedside.
 
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  
3

Forward Looking Statement

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, expectations regarding pipeline expansion, the expected cash runway, and BioLineRx's business strategy. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials, and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials, whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; and statements as to the impact of the political and security situation in Israel on BioLineRx's business, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2025. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contacts:

United States
Irina Koffler
LifeSci Advisors, LLC
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
4

BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(UNAUDITED)

   
December 31,
    
June 30,
  
   
2024
    
2025
  
   
in USD thousands
  
Assets
            
CURRENT ASSETS
            
Cash and cash equivalents
    
10,436
      
7,189
  
Short-term bank deposits
    
9,126
      
20,970
  
Trade receivables
    
2,476
      
78
  
Prepaid expenses
    
443
      
572
  
Other receivables
    
1,478
      
203
  
Inventory
    
3,145
      
2,850
  
Total current assets
    
27,104
      
31,862
  
                 
NON-CURRENT ASSETS
                
Property and equipment, net
    
386
      
197
  
Right-of-use assets, net
    
967
      
800
  
Intangible assets, net
    
10,449
      
10,408
  
Total non-current assets
    
11,802
      
11,405
  
Total assets
    
38,906
      
43,267
  
                 
Liabilities and equity
                
CURRENT LIABILITIES
                
Current maturities of long-term loan
    
4,479
      
4,479
  
Accounts payable and accruals:
                
Trade
    
5,583
      
3,465
  
Other
    
3,131
      
2,767
  
Current maturities of lease liabilities
    
522
      
408
  
Warrants
    
1,691
      
4,360
  
Total current liabilities
    
15,406
      
15,479
  
                 
NON-CURRENT LIABILITIES
                
Long-term loan, net of current maturities
    
8,958
      
6,718
  
Lease liabilities
    
1,081
      
998
  
Total non-current liabilities
    
10,039
      
7,716
  
COMMITMENTS AND CONTINGENT LIABILITIES
                
Total liabilities
    
25,445
      
23,195
  
                 
EQUITY
                
Ordinary shares
    
38,097
      
71,819
  
Share premium
    
353,693
      
327,475
  
Warrants
    
5,367
      
3,686
  
Capital reserve
    
17,547
      
17,148
  
Other comprehensive loss
    
(1,416
)
    
(1,416
)
Accumulated deficit
    
(399,827
)
    
(398,640
)
Total equity
    
13,461
      
20,072
  
Total liabilities and equity
    
38,906
      
43,267
  

5

BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)

   
Three months ended June 30,
    
Six months ended June 30,
  
   
2024
    
2025
    
2024
    
2025
  
   
in USD thousands
    
In USD thousands
  
REVENUES:
                        
License revenues
    
3,550
      
304
      
9,481
      
559
  
Product sales, net
    
1,843
      
-
      
2,767
      
-
  
Total revenues
    
5,393
      
304
      
12,248
      
559
  
COST OF REVENUES
    
(897
)
    
(72
)
    
(2,352
)
    
(106
)
GROSS PROFIT
    
4,496
      
232
      
9,896
      
453
  
RESEARCH AND DEVELOPMENT EXPENSES
    
(2,225
)
    
(2,326
)
    
(4,719
)
    
(3,949
)
SALES AND MARKETING EXPENSES
    
(6,415
)
    
-
      
(12,757
)
    
-
  
GENERAL AND ADMINISTRATIVE EXPENSES
    
(1,629
)
    
(209
)
    
(3,015
)
    
(1,198
)
OPERATING LOSS
    
(5,773
)
    
(2,303
)
    
(10,595
)
    
(4,694
)
NON-OPERATING INCOME (EXPENSES), NET
    
7,807
      
(1,851
)
    
12,297
      
5,793
  
FINANCIAL INCOME
    
535
      
490
      
1,100
      
784
  
FINANCIAL EXPENSES
    
(2,085
)
    
(276
)
    
(3,014
)
    
(696
)
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)
    
484
      
(3,940
)
    
(212
)
    
1,187
  
                                 
   
in USD
    
In USD
  
EARNINGS (LOSS) PER ORDINARY SHARE - BASIC AND DILUTED
    
0.00
      
(0.00
)
    
(0.00
)
    
0.00
  
                                 
WEIGHTED AVERAGE NUMBER OF SHARES USED IN
CALCULATION OF EARNINGS (LOSS) PER ORDINARY SHARE
    
1,197,582,901
      
2,369,687,536
      
1,142,221,033
      
2,294,127,662
  

6

BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY
(UNAUDITED)

   
Ordinary
shares
    
Share
premium
    
Warrants
    
Capital
reserve
    
Other
comprehensive loss
    
Accumulated
deficit
    
Total
  
   
in USD thousands
  
BALANCE AT JANUARY 1, 2024
    
31,355
      
355,482
      
1,408
      
17,000
      
(1,416
)
    
(390,606
)
    
13,223
  
CHANGES FOR SIX MONTHS ENDED
JUNE 30, 2024:
                                                        
Issuance of share capital and warrants, net
    
3,056
      
(3,056
)
    
-
      
-
      
-
      
-
      
-
  
Employee stock options expired
    
-
      
-
      
-
      
(66
)
    
-
      
-
      
(66
)
Share-based compensation
    
-
      
-
      
-
      
1,036
      
-
      
-
      
1,036
  
Comprehensive loss for the period
    
-
      
-
      
-
      
-
      
-
      
(212
)
    
(212
)
BALANCE AT JUNE 30, 2024
    
34,411
      
352,426
      
1,408
      
17,970
      
(1,416
)
    
(390,818
)
    
13,891
  

   
Ordinary
shares
    
Share
premium
    
Warrants
    
Capital
reserve
    
Other
comprehensive loss
    
Accumulated
deficit
    
Total
  
   
in USD thousands
  
BALANCE AT JANUARY 1, 2025
    
38,097
      
353,693
      
5,367
      
17,547
      
(1,416
)
    
(399,827
)
    
13,461
  
CHANGES FOR SIX MONTHS ENDED
JUNE 30, 2025:
                                                        
Issuance of share capital, pre-funded warrants and warrants, net
    
25,664
      
(20,988
)
    
501
      
-
      
-
      
-
      
5,177
  
Pre-funded warrants exercised
    
8,058
      
(5,876
)
    
(2,182
)
    
-
      
-
      
-
      
-
  
Employee stock options expired
    
-
      
646
      
-
      
(646
)
    
-
      
-
      
-
  
Share-based compensation
    
-
      
-
      
-
      
247
      
-
      
-
      
247
  
Comprehensive income for the period
    
-
      
-
      
-
      
-
      
-
      
1,187
      
1,187
  
BALANCE AT JUNE 30, 2025
    
71,819
      
327,475
      
3,686
      
17,148
      
(1,416
)
    
(398,640
)
    
20,072
  

7

BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS
(UNAUDITED)
 
   
Six months ended
June 30,
  
   
2024
    
2025
  
   
in USD thousands
  
             
CASH FLOWS - OPERATING ACTIVITIES
            
Comprehensive income (loss) for the period
    
(212
)
    
1,187
  
Adjustments required to reflect net cash used in operating activities
 (see appendix below)
    
(25,226
)
    
(3,955
)
Net cash used in operating activities
    
(25,438
)
    
(2,768
)
                 
CASH FLOWS - INVESTING ACTIVITIES
                
Investments in short-term deposits
    
(20,559
)
    
(24,818
)
Maturities of short-term deposits
    
28,660
      
12,926
  
Sale (purchase) of property and equipment
    
(59
)
    
11
  
Net cash provided by (used in) investing activities
    
8,042
      
(11,881
)
                 
CASH FLOWS - FINANCING ACTIVITIES
                
Issuance of share capital and warrants, net of issuance costs
    
5,565
      
13,554
  
Net proceeds from loan
    
19,223
      
-
  
Repayments of loan
    
(1,547
)
    
(2,240
)
Repayments of lease liabilities
    
(256
)
    
(262
)
Net cash provided by financing activities
    
22,985
      
11,052
  
                 
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
    
5,589
      
(3,597
)
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD
    
4,255
      
10,436
  
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS
    
(221
)
    
350
  
CASH AND CASH EQUIVALENTS - END OF PERIOD
    
9,623
      
7,189
  

8
 
BioLineRx Ltd.
APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS
(UNAUDITED)
 
   
Six months ended
June 30,
  
   
2024
    
2025
  
   
in USD thousands
  
             
Adjustments required to reflect net cash used in operating activities:
            
Income and expenses not involving cash flows:
            
Depreciation and amortization
    
1,373
      
341
  
Exchange differences on cash and cash equivalents
    
221
      
(350
)
Fair value adjustments of warrants
    
(12,845
)
    
(6,410
)
Warrant issuance costs
    
642
      
702
  
Share-based compensation
    
970
      
247
  
Interest on short-term deposits
    
201
      
48
  
Interest on loan
    
1,997
      
-
  
Exchange differences on lease liabilities
    
189
      
110
  
     
(7,252
)
    
(5,312
)
                 
Changes in operating asset and liability items:
                
Decrease (increase) in trade receivables
    
(2,821
)
    
2,398
  
Decrease (increase) in prepaid expenses and other receivables
    
(359
)
    
1,146
  
Decrease (increase) in inventory
    
(1,681
)
    
295
  
Decrease in accounts payable and accruals
    
(5,633
)
    
(2,482
)
Decrease in contract liabilities
    
(7,480
)
    
-
  
     
(17,974
)
    
1,357
  
     
(25,226
)
    
(3,955
)
                 
Supplemental information on interest received in cash
    
931
      
583
  
                 
Supplemental information on interest paid in cash
    
971
      
694
  
                 
Supplemental information on non-cash transactions:
                
Changes in right-of-use asset and lease liabilities
    
58
      
45
  
Warrant issuance costs
    
207
      
-
  

9